The changing epidemiology of fungal infections
- PMID: 37804792
- DOI: 10.1016/j.mam.2023.101215
The changing epidemiology of fungal infections
Erratum in
-
Corrigendum to "The changing epidemiology of fungal infections" [Mol. Aspect. Med. 94 (2023) 101215].Mol Aspects Med. 2024 Feb;95:101240. doi: 10.1016/j.mam.2023.101240. Epub 2023 Dec 27. Mol Aspects Med. 2024. PMID: 38154429 No abstract available.
Abstract
Invasive fungal diseases are common complications in critically ill patients and in those with significant underlying imbalanced immune systems. Fungal co-, and/or super-infections are emerging and have become a rising concern within the last few years. In Europe, cases of candidiasis and aspergillosis dominate, followed by mucormycosis in India. Epidemiological studies show an increasing trend in the incidence of all three entities. Parallel to this, a shift within the underlying fungal pathogens is observed. More non-albicans Candida infections and aspergillosis with cryptic species are on the rise; cryptic species may cover intrinsic resistance to azoles and other antifungal drugs. The recent COVID-19 pandemic led to a significantly increasing incidence of invasive fungal diseases among hospitalized patients.
Keywords: Aspergillosis; Candidiasis; Epidemiology; Invasive fungal disease; Mucormycosis; Rare fungi.
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare no conflict of interest with this manuscript.
Similar articles
-
The changing face of epidemiology of invasive fungal disease in Europe.Mycoses. 2009 May;52(3):197-205. doi: 10.1111/j.1439-0507.2009.01691.x. Mycoses. 2009. PMID: 19391253 Review.
-
Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.Dan Med J. 2016 Oct;63(10):B5288. Dan Med J. 2016. PMID: 27697142 Review.
-
Caspofungin acetate for treatment of invasive fungal infections.Ann Pharmacother. 2003 Jan;37(1):90-8. doi: 10.1345/aph.1C114. Ann Pharmacother. 2003. PMID: 12503942 Review.
-
The changing epidemiology of invasive fungal infections: new threats.Int J Antimicrob Agents. 2006 Jun;27 Suppl 1:3-6. doi: 10.1016/j.ijantimicag.2006.03.006. Epub 2006 May 16. Int J Antimicrob Agents. 2006. PMID: 16707250 Review.
-
Increasing fungal infections in the intensive care unit.Surg Infect (Larchmt). 2006;7 Suppl 2:S93-6. doi: 10.1089/sur.2006.7.s2-93. Surg Infect (Larchmt). 2006. PMID: 16895517 Review.
Cited by
-
Unveiling the antifungal mechanisms of CTP, a new copper(II)-theophylline/1,10-phenanthroline complex, on drug-resistant non-albicans Candida species.Biometals. 2024 Oct;37(5):1237-1253. doi: 10.1007/s10534-024-00605-1. Epub 2024 Jun 14. Biometals. 2024. PMID: 38874822
-
Efficacy and Safety of Amphotericin B Colloidal Dispersion for Patients with Invasive Fungal Disease and Febrile Neutropenia: A Registry-Based, Multicenter, Retrospective, Real-World Study.Infect Drug Resist. 2025 May 13;18:2475-2487. doi: 10.2147/IDR.S494985. eCollection 2025. Infect Drug Resist. 2025. PMID: 40384797 Free PMC article.
-
Role of liposomal amphotericin B in intensive care unit: an expert opinion paper.J Anesth Analg Crit Care. 2025 Apr 29;5(1):23. doi: 10.1186/s44158-025-00236-z. J Anesth Analg Crit Care. 2025. PMID: 40301956 Free PMC article. Review.
-
The Expanding Mycovirome of Aspergilli.J Fungi (Basel). 2024 Aug 17;10(8):585. doi: 10.3390/jof10080585. J Fungi (Basel). 2024. PMID: 39194910 Free PMC article. Review.
-
Cryptococcus neoformans/gattii and Histoplasma capsulatum var. capsulatum infections on tissue sections: Diagnostic pitfalls and relevance of an integrated histomolecular diagnosis.Med Mycol. 2024 Dec 27;63(1):myae126. doi: 10.1093/mmy/myae126. Med Mycol. 2024. PMID: 39732625 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical